49 related articles for article (PubMed ID: 38683590)
1. L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy.
Hayashi K; Anzai N
J Pharmacol Sci; 2022 Jan; 148(1):31-40. PubMed ID: 34924127
[TBL] [Abstract][Full Text] [Related]
2. L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer.
Norrsell R; Bauden M; Andersson R; Ansari D
Cancer Control; 2024; 31():10732748241251583. PubMed ID: 38683590
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.
Kaira K; Sunose Y; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Segawa A; Furuya M; Mori M; Oyama T; Takeyoshi I
Br J Cancer; 2012 Aug; 107(4):632-8. PubMed ID: 22805328
[TBL] [Abstract][Full Text] [Related]
4. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
Häfliger P; Charles RP
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100853
[TBL] [Abstract][Full Text] [Related]
5. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
[TBL] [Abstract][Full Text] [Related]
6. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
[TBL] [Abstract][Full Text] [Related]
7. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.
Nishikubo K; Ohgaki R; Liu X; Okanishi H; Xu M; Endou H; Kanai Y
Cancer Cell Int; 2023 Jun; 23(1):116. PubMed ID: 37322479
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
[TBL] [Abstract][Full Text] [Related]
10. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells.
Suzuki T; Kishikawa T; Sato T; Takeda N; Sugiura Y; Seimiya T; Sekiba K; Ohno M; Iwata T; Ishibashi R; Otsuka M; Koike K
Cancer Gene Ther; 2022 May; 29(5):505-518. PubMed ID: 33833413
[TBL] [Abstract][Full Text] [Related]
11. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Najumudeen AK; Ceteci F; Fey SK; Hamm G; Steven RT; Hall H; Nikula CJ; Dexter A; Murta T; Race AM; Sumpton D; Vlahov N; Gay DM; Knight JRP; Jackstadt R; Leach JDG; Ridgway RA; Johnson ER; Nixon C; Hedley A; Gilroy K; Clark W; Malla SB; Dunne PD; Rodriguez-Blanco G; Critchlow SE; Mrowinska A; Malviya G; Solovyev D; Brown G; Lewis DY; Mackay GM; Strathdee D; Tardito S; Gottlieb E; ; Takats Z; Barry ST; Goodwin RJA; Bunch J; Bushell M; Campbell AD; Sansom OJ
Nat Genet; 2021 Jan; 53(1):16-26. PubMed ID: 33414552
[TBL] [Abstract][Full Text] [Related]
12. α-Emitting cancer therapy using
Kaneda-Nakashima K; Zhang Z; Manabe Y; Shimoyama A; Kabayama K; Watabe T; Kanai Y; Ooe K; Toyoshima A; Shirakami Y; Yoshimura T; Fukuda M; Hatazawa J; Nakano T; Fukase K; Shinohara A
Cancer Sci; 2021 Mar; 112(3):1132-1140. PubMed ID: 33277750
[TBL] [Abstract][Full Text] [Related]
13. Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment.
Zhang J; Xu Y; Li D; Fu L; Zhang X; Bao Y; Zheng L
Front Chem; 2020; 8():564809. PubMed ID: 33195053
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies.
Xu R; Yang J; Ren B; Wang H; Yang G; Chen Y; You L; Zhao Y
Front Oncol; 2020; 10():572722. PubMed ID: 33117704
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]